Investors

ImmuCell Corporation (Nasdaq: ICCC) has developed the First Defense® product line to deliver Immediate Immunity™ against E. coli, coronavirus, and rotavirus infections, the primary pathogens that cause scours (uncontrolled diarrhea), which is the leading disease risk to newborn dairy and beef calves. The Company estimates the cost of scours in the US to be over $700 million per year. The use of First Defense® immediately after birth enables producers to realize the genetic potential of their newborn livestock assets.

The Company is also in the final stages of achieving FDA approval for Re-Tain®, a bacteriocin-based product to treat subclinical mastitis in lactating cows without the use of traditional human antibiotics. Mastitis infections result in approximately $2 BILLION in economic losses to the U.S. dairy industry annually. Reducing the use of antibiotics in the human food chain is a national imperative.

Investor Information

02-25-25 – ImmuCell Announces Unaudited Financial Results for the Quarter and Year Ended December 31, 2024

March 2025 Corporate Presentation

Form 10K

Recent News

04-08-25 ImmuCell Announces Preliminary, Unaudited Sales Results for Q1 of 2025

04-07-25 ImmuCell Hires Chief Financial Officer

04-02-25 ImmuCell Announces Initiation of Investigational Product Use of Re-Tain®

View all press releases

Annual Meeting of Stockholders

Thursday, June 12, 2025 at 9:30 AM ET

Proxy Statement

Our Core Technology

CEO Michael Brigham discusses ImmuCell’s core technology with Dr. Joseph H. Crabb former Chief Scientific Officer and VP of Product Development for ImmuCell and the developer of First Defense.

Download Transcript

Listen to Interview